Literature DB >> 7949212

Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs.

G R Rutteman1, J A Foekens, H Portengen, J H Vos, M A Blankenstein, E Teske, C J Cornelisse, W Misdorp.   

Abstract

Epidermal growth factor (EGFR), oestrogen (ER), and progestin (PR) receptor concentrations were determined by radioligand binding assay in non-affected mammary tissues (n = 13) and benign (n = 11) and primary/locally recurrent malignant proliferative mammary lesions (n = 45) and metastases (n = 19) in 65 female dogs. The number of specimens expressing EGFR was not significantly different among these tissues, but EGFR concentration was lower in metastases (P = 0.02) than in benign or primary/locally recurrent malignant lesions not mixed with non-affected mammary tissue. The presence of non-affected mammary tissue in primary cancer specimens was noticed as a factor that may influence results of receptor measurements. No relation was found between the expression of EGFR and that of ER or PR in non-affected or in tumorous mammary tissues. It was concluded that in the dog mammary gland EGFR expression is not associated with conditions of steroid receptor absence of biological agressiveness of neoplastic growth.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949212     DOI: 10.1007/bf00666057

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  38 in total

Review 1.  Growth factors and cancer.

Authors:  A S Goustin; E B Leof; G D Shipley; H L Moses
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

2.  Nuclear mechanisms for the increase of epidermal growth factor receptor in squamous cell carcinoma.

Authors:  F J Hendler; C S Richards; A Shum; D Burns; S Schaefer; B Ozanne
Journal:  Trans Assoc Am Physicians       Date:  1985

3.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

4.  Prognostic factors in canine mammary cancer.

Authors:  W Misdorp; A A Hart
Journal:  J Natl Cancer Inst       Date:  1976-04       Impact factor: 13.506

5.  Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.

Authors:  M Fekete; J L Wittliff; A V Schally
Journal:  J Clin Lab Anal       Date:  1989       Impact factor: 2.352

6.  Receptors for epidermal growth factor and estradiol in canine mammary tumors.

Authors:  V R Nerurkar; R Seshadri; R Mulherkar; C S Ishwad; V S Lalitha; S N Naik
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

7.  Tumours and dysplasias of the mammary gland.

Authors:  J F Hampe; W Misdorp
Journal:  Bull World Health Organ       Date:  1974       Impact factor: 9.408

Review 8.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.

Authors:  J G Klijn; P M Berns; P I Schmitz; J A Foekens
Journal:  Endocr Rev       Date:  1992-02       Impact factor: 19.871

9.  Expression of epidermal growth factor, transforming growth factor-alpha and their receptor genes in human gastric carcinomas; implication for autocrine growth.

Authors:  K Yoshida; E Kyo; T Tsujino; T Sano; M Niimoto; E Tahara
Journal:  Jpn J Cancer Res       Date:  1990-01

Review 10.  Growth control and differentiation in mammary epithelial cells.

Authors:  F Borellini; T Oka
Journal:  Environ Health Perspect       Date:  1989-03       Impact factor: 9.031

View more
  1 in total

Review 1.  Theranostics Aspects of Various Nanoparticles in Veterinary Medicine.

Authors:  Ding-Ping Bai; Xin-Yu Lin; Yi-Fan Huang; Xi-Feng Zhang
Journal:  Int J Mol Sci       Date:  2018-10-24       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.